Table 3.
Effects of sesamin on thrombosis.
| Reference | Experimental Model | Dosage | Administration Mode | Administration Duration | Experimental N | Response |
|---|---|---|---|---|---|---|
| Cell and Cell Lines | ||||||
| Ku et al. (2013) | HUVECs | 0.5, 1, 2, 5, 10, 20, 50 µM | N/A | 10 min − 18 h | 3 | Negligible effect on coagulation, bleeding time, thrombin production and activity, FXa production and activity, platelet aggregation, fibrin polymerization, and plasminogen activator inhibitor type 1 (PAI-1)/tissue-type plasminogen activator (t-PA) ratio |
| Animal Models | ||||||
| Noguchi et al. (2001) | Stroke-prone spontaneously hypertensive rats | 1000 mg/kg | Oral | 5 weeks | 3 | Increase in the number of He-Ne laser pulses required to induce thrombosis |
| Kinugasa et al. (2011) | C57BL/6 mice | 1, 10 mmol/L 3 mmol/L (7.7 mg/kg) |
Intra-arterial Oral |
10 min 2 h |
7 (1 mmol/L), 6 (10 mmol/L) 6 |
Increase in the number of He-Ne laser pulses required to induce thrombosis |
| Ku et al. (2013) | ICR mice | 7 µg | Intravenous | 1 hr | 5 | Negligible effect on coagulation, bleeding time, thrombin production and activity, FXa production and activity, platelet aggregation, fibrin polymerization, and plasminogen activator inhibitor type 1 (PAI-1)/tissue-type plasminogen activator (t-PA) ratio |